FOI Request
- Disclosure ID
- FOI/01085
- Request Date
- July 4, 2016
- Subject
- Neuroendocrine Tumours July 2016
- Description
1. In your trust, please provide the number of patients treated in the last 12 months who have been diagnosed [any diagnosis position] with neuroendocrine tumours <ol start=”2″> <li>Of these how many have carcinoid syndrome (E34.0)?</li> </ol> <ol start=”3″> <li>Of the patients with neuroendocrine tumours (NETs), how many received with the following treatments:</li> </ol> <ul> <li>Somatuline Autogel (lanreotide)</li> <li>Somatuline LA (lanreotide)</li> <li>Sandostatin LAR (octreotide LAR)</li> <li>Octreotide </li> <li>Afinitor (everolimus) </li> <li>Sutent (sunitinib) </li> </ul> <ol start=”4″> <li>Please provide the number of patients treated in the last 12 months who have been diagnosed [any diagnosis position] with acromegaly (ICD10 code E220 or ICD10 code D352), with the following treatments:</li> </ol> <ul> <li>Somatuline Autogel (lanreotide)</li> <li>Somatuline LA (lanreotide)</li> <li>Sandostatin LAR (octreotide LAR)</li> <li>Octreotide </li> <li>Somavert (pegvisomant) </li> <li>Signifor (pasireotide pamoate) </li> </ul>
- Response
Using the patient hospital numbers from the PAS system (780 patients), We checked through the patient medication issues and supplied the patient count based on the request drugs. However as the pharmacy system doesn’t store clinical indication, We are unable to guarantee the indication / diagnosis the medication was used for. <ol> <li>780 Patients</li> <li>1 Patient</li> <li>of patients issued drugs:</li> </ol> <table width=”549″> <tbody> <tr> <td width=”283″> </td> <td width=”266″><strong>No. Patients</strong></td> </tr> <tr> <td width=”283″><strong>Somatuline Autogel (lanreotide)</strong></td> <td width=”266″>0</td> </tr> <tr> <td width=”283″><strong>Somatuline LA (lanreotide)</strong></td> <td width=”266″>0</td> </tr> <tr> <td width=”283″><strong>Sandostatin LAR (lanreotide LAR)</strong></td> <td width=”266″>0</td> </tr> <tr> <td width=”283″><strong>Octreotide </strong></td> <td width=”266″>21</td> </tr> <tr> <td width=”283″><strong>Afinitor (everolimus)</strong></td> <td width=”266″>3</td> </tr> <tr> <td width=”283″><strong>Sutent (sunitinib)</strong></td> <td width=”266″>4</td> </tr> </tbody> </table> <ol start=”4″> <li>of patients issued with the following drugs filtered by selected diagnosis codes:</li> </ol> <table width=”543″> <tbody> <tr> <td width=”307″> </td> <td width=”236″><strong>No. Patients</strong></td> </tr> <tr> <td width=”307″><strong>Somatuline Autogel (lanreotide)</strong></td> <td width=”236″>0</td> </tr> <tr> <td width=”307″><strong>Somatuline LA (lanreotide)</strong></td> <td width=”236″>0</td> </tr> <tr> <td width=”307″><strong>Sandostatin LAR (lanreotide LAR)</strong></td> <td width=”236″>0</td> </tr> <tr> <td width=”307″><strong>Octreotide </strong></td> <td width=”236″>1</td> </tr> <tr> <td width=”307″><strong>Afinitor (everolimus)</strong></td> <td width=”236″>1</td> </tr> <tr> <td width=”307″><strong>Sutent (sunitinib)</strong></td> <td width=”236″>3</td> </tr> </tbody> </table>